Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study

Autor: Niccolò Gori, Alvise Sernicola, Ersilia Tolino, Maria Mariano, Marco Galluzzo, Gaia Moretta, Rosa Coppola, Andrea D’Alessio, Massimo Sansone, Virginia Maffei, Claudia Paolino, Cristian Ferrao, Lauro Cascia, Paola Addio, Lucia Di Nardo, Andrea Chiricozzi, Ester Del Duca, Antonio Cristaudo, Luca Bianchi, Sabatino Pallotta, Vincenzo Panasiti, Giovanni Pellacani, Concetta Potenza, Ketty Peris
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Druh dokumentu: article
ISSN: 0954-6634
1471-1753
09546634
DOI: 10.1080/09546634.2023.2230685
Popis: Objectives The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe atopic dermatitis (AD), and to investigate the clinical, demographic and predictive factors influencing the patients’ treatment persistence. Material and methods This study included adult patients affected by moderate-to-severe AD treated with dupilumab for at least 16 weeks who visited 7 dermatologic outpatient clinics in Lazio, Italy, from January 2019 until August 2021. Results A total of 659 adult patients (345 male [52.3%], mean age: 42.8 years) with an average treatment duration of 23.3 months were enrolled in the study. Overall, 88.6% and 76.1% of patients were still on treatment after 12 and 24 months, respectively. The drug survival rate for discontinuation due to AEs and dupilumab ineffectiveness was 95.0% at 12 months and 90.0% at 24 months. The main reasons for drug discontinuation included inefficacy (29.6%), failed compliance (17.4%), persistent efficacy (20.4%) and adverse events (7.8%). Adult AD onset (≥18 years) and EASI score severity measured at the last follow-up visit were the only factors significantly associated with lower drug survival. Conclusion This study revealed an increased cumulative probability of dupilumab survival at 2 years, reflected by a sustained effectiveness and a favorable safety profile of the drug.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje